Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 28

1.

The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism.

McGraw J, Cherney M, Bichler K, Gerhardt A, Nauman M.

Toxicol Lett. 2019 Oct 15;315:9-13. doi: 10.1016/j.toxlet.2019.08.003. Epub 2019 Aug 10.

PMID:
31408697
2.

The Effect of Eplerenone in Chronic Central Serous Chorioretinopathy Refractory to Photodynamic Therapy.

Karagiannis D, Parikakis E, Kontomichos L, Batsos G, Chatziralli I.

Semin Ophthalmol. 2019;34(6):436-441. doi: 10.1080/08820538.2019.1642920. Epub 2019 Jul 16.

PMID:
31309849
3.

The selective mineralocorticoid receptor modulator AZD9977 reveals differences in mineralocorticoid effects of aldosterone and fludrocortisone.

Bamberg K, William-Olsson L, Johansson U, Jansson-Löfmark R, Hartleib-Geschwindner J.

J Renin Angiotensin Aldosterone Syst. 2019 Jan-Mar;20(1):1470320319827449. doi: 10.1177/1470320319827449.

4.

An unusual case of multifocal central serous chorioretinopathy with low serum cortisol managed using eplerenone.

Aggarwal K, Agarwal A, Gupta V.

Indian J Ophthalmol. 2019 Jan;67(1):167-170. doi: 10.4103/ijo.IJO_651_18.

5.

EPURE Transplant (Eplerenone in Patients Undergoing Renal Transplant) study: study protocol for a randomized controlled trial.

Girerd S, Frimat L, Ducloux D, Le Meur Y, Mariat C, Moulin B, Mousson C, Rieu P, Dali-Youcef N, Merckle L, Lepage X, Rossignol P, Girerd N, Jaisser F.

Trials. 2018 Oct 30;19(1):595. doi: 10.1186/s13063-018-2956-1.

6.

Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy.

Bourke JP, Bueser T, Quinlivan R.

Cochrane Database Syst Rev. 2018 Oct 16;10:CD009068. doi: 10.1002/14651858.CD009068.pub3.

PMID:
30326162
7.

Collagen biomarker bioprofiles predicting the antifibrotic response to eplerenone in myocardial infarction: findings from the REMINDER trial.

Ferreira JP, Barros A, Pitt B, Montalescot G, de Sa EL, Hamm CW, Flather M, Verheugt F, Shi H, Leite-Moreira A, Vincent J, Rossignol P, Zannad F.

Clin Res Cardiol. 2018 Dec;107(12):1192-1195. doi: 10.1007/s00392-018-1373-5. Epub 2018 Sep 27. No abstract available.

PMID:
30264283
8.

Mineralocorticoid receptor antagonism improves parenchymal arteriole dilation via a TRPV4-dependent mechanism and prevents cognitive dysfunction in hypertension.

Diaz-Otero JM, Yen TC, Fisher C, Bota D, Jackson WF, Dorrance AM.

Am J Physiol Heart Circ Physiol. 2018 Nov 1;315(5):H1304-H1315. doi: 10.1152/ajpheart.00207.2018. Epub 2018 Aug 17.

PMID:
30118343
9.

A comparison of the effects of selective and non-selective mineralocorticoid antagonism on glucose homeostasis of heart failure patients with glucose intolerance or type II diabetes: A randomized controlled double-blind trial.

Korol S, White M, O'Meara E, Tournoux F, Racine N, Ducharme A, Rouleau JL, Liszkowski M, Mansour A, Jutras M, Guertin MC, Bernier M, Lavoie J, Leclair G, Neagoe PE, Chaar D, Sirois MG, de Denus S.

Am Heart J. 2018 Oct;204:190-195. doi: 10.1016/j.ahj.2018.07.002. Epub 2018 Jul 10.

PMID:
30097164
10.

Mineralocorticoid receptor blockade improves arginine transport and nitric oxide generation through modulation of cationic amino acid transporter-1 in endothelial cells.

Shashar M, Hod T, Chernichovski T, Angel A, Kazan S, Grupper A, Naveh S, Kliuk-Ben Bassat O, Weinstein T, Schwartz IF.

Nitric Oxide. 2018 Nov 1;80:24-31. doi: 10.1016/j.niox.2018.07.007. Epub 2018 Jul 26.

PMID:
30056252
11.

Mineralocorticoid receptor antagonism improves diastolic dysfunction in chronic kidney disease in mice.

Bonnard B, Pieronne-Deperrois M, Djerada Z, Elmoghrabi S, Kolkhof P, Ouvrard-Pascaud A, Mulder P, Jaisser F, Messaoudi S.

J Mol Cell Cardiol. 2018 Aug;121:124-133. doi: 10.1016/j.yjmcc.2018.06.008. Epub 2018 Jul 6.

PMID:
29981797
12.

The role of mineralocorticoid receptor antagonists in patients with acute myocardial infarction: Is the evidence reflective of modern clinical practice?

Hinton J, Mahmoudi M, Myat A, Curzen N.

Cardiovasc Revasc Med. 2018 Jun;19(4):452-456. doi: 10.1016/j.carrev.2018.04.012. Epub 2018 Apr 17. Review. No abstract available.

PMID:
29730238
13.

Individual participant data analysis of two trials on aldosterone blockade in myocardial infarction.

Beygui F, Van Belle E, Ecollan P, Machecourt J, Hamm CW, Lopez De Sa E, Flather M, Verheugt FWA, Vicaut E, Zannad F, Pitt B, Montalescot G.

Heart. 2018 Nov;104(22):1843-1849. doi: 10.1136/heartjnl-2018-312950. Epub 2018 Apr 25.

PMID:
29695512
14.

Randomized, Placebo-Controlled Trial to Evaluate Effects of Eplerenone on Metabolic and Inflammatory Indices in HIV.

Srinivasa S, Fitch KV, Wong K, O'Malley TK, Maehler P, Branch KL, Looby SE, Burdo TH, Martinez-Salazar EL, Torriani M, Lyons SH, Weiss J, Feldpausch M, Stanley TL, Adler GK, Grinspoon SK.

J Clin Endocrinol Metab. 2018 Jun 1;103(6):2376-2384. doi: 10.1210/jc.2018-00330.

15.

The Effect of Mineralocorticoid Receptor Antagonists on Recruitment and Function of Endothelial Progenitor Cells in Patients with Congestive Heart Failure.

Levi A, Leshem-Lev D, Weissler-Snir A, Hasin T, Mats I, Murninkas D, Kornowski R, Lev EI, Ben-Gal T.

Isr Med Assoc J. 2018 Apr;20(4):233-238.

16.

Eplerenone Modulates Interleukin-33/sST2 Signaling and IL-1β in Left Ventricular Systolic Dysfunction After Acute Myocardial Infarction.

Chen B, Geng J, Gao SX, Yue WW, Liu Q.

J Interferon Cytokine Res. 2018 Mar;38(3):137-144. doi: 10.1089/jir.2017.0067. Epub 2018 Mar 12.

PMID:
29565745
17.

Unanticipated increases in hepatic steatosis among human immunodeficiency virus patients receiving mineralocorticoid receptor antagonist eplerenone for non-alcoholic fatty liver disease.

Chaudhury CS, Purdy JB, Liu CY, Morse CG, Stanley TL, Kleiner D, Hadigan C.

Liver Int. 2018 May;38(5):797-802. doi: 10.1111/liv.13734. Epub 2018 Mar 31.

PMID:
29509992
18.

Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension.

Boehm M, Arnold N, Braithwaite A, Pickworth J, Lu C, Novoyatleva T, Kiely DG, Grimminger F, Ghofrani HA, Weissmann N, Seeger W, Lawrie A, Schermuly RT, Kojonazarov B.

BMC Pulm Med. 2018 Mar 2;18(1):41. doi: 10.1186/s12890-018-0604-x.

19.

Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator.

Erlandsson F, Albayaty M, Chialda L, Ericsson H, Amilon C, Nelander K, Jansson-Löfmark R, Wernevik L, Kjaer M, Bamberg K, Hartleib-Geschwindner J.

Br J Clin Pharmacol. 2018 Jul;84(7):1486-1493. doi: 10.1111/bcp.13562. Epub 2018 Apr 22.

20.

Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone's Antifibrotic Activity.

Grune J, Beyhoff N, Smeir E, Chudek R, Blumrich A, Ban Z, Brix S, Betz IR, Schupp M, Foryst-Ludwig A, Klopfleisch R, Stawowy P, Houtman R, Kolkhof P, Kintscher U.

Hypertension. 2018 Apr;71(4):599-608. doi: 10.1161/HYPERTENSIONAHA.117.10360. Epub 2018 Feb 5.

PMID:
29437893

Supplemental Content

Loading ...
Support Center